​​Our Vision is to Deliver Disease-Modifying Therapies for CMT1A and Related Neurological Indications.

 ​

The Challenge

These debilitating disorders still lack approved therapies that can halt or reverse disease progression. This profound unmet need calls for a new approach to discovery and development.

​

How We Aim to Change It

CELLTIUM is building a new model for neurotherapeutics that integrates disease biology, quantitative phenotyping, and data-driven decision-making from the outset. Our goal is to translate complex biological insights into first-in-class medicines with the potential to change the course of disease.

​

Our Approach

Our research is grounded in highly predictive cellular and in vivo models designed to capture the core biology of neurological disorders. Building on this foundation, our proprietary PRECISION™ platform combines AI/ML and multimodal data to generate robust phenomic signatures that accelerate target discovery, candidate prioritization, and lead optimization.

​

The Impact We Seek

By uniting experimental neurobiology with advanced computational tools, we aim to improve the predictability, efficiency, and clinical success of neurological drug development. Ultimately, we strive to deliver therapies that go beyond symptom management and meaningfully modify disease.

​

Our Commitment

We hold our science to the highest standard, with the same rigor and urgency we would demand for ourselves and our families.